Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00184964|
Recruitment Status : Unknown
Verified June 2008 by Radboud University.
Recruitment status was: Recruiting
First Posted : September 16, 2005
Last Update Posted : June 4, 2008
CT-PET image fusion has the potential to differentiate 'tumor' from 'atelectasis' much better than the CT-scan in patients with non-small cell lung cancer who also have atelectasis.
This however has never been validated on a histological level. In this study patients with non small cell lung cancer and atelectasis who are eligible for surgery undergo a CT-scan and a PET-scan prior to surgery.
The resection specimen will be compared to the preoperative imaging.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Non Small Cell Lung||Procedure: CT-scan, PET-scan||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis With Histological Examination of the Resected Specimen|
|Study Start Date :||June 2004|
- Histological validation of CT-PET image fusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184964
|Contact: Dominic A Schinagl, MDfirstname.lastname@example.org|
|Radboud University Nijmegen Medical Centre||Recruiting|
|Nijmegen, Gelderland, Netherlands, 6500HB|
|Contact: Dominic A Schinagl, MD +31243614515 email@example.com|
|Principal Investigator: Dominic A Schinagl, MD|
|Study Director:||Jan Bussink, MD, PhD||Radiation oncologist, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands|